A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2021

Primary Completion Date

December 5, 2022

Study Completion Date

May 17, 2023

Conditions

Chronic Hepatitis B

Interventions

DRUG

NrtIs

Subjects will receive NrtIs therapy for 24 weeks.

DRUG

HH-003

Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.

DRUG

HH-003+NrtIs

Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.

Trial Locations (1)

Nanfang Hospital, Southern Medical University, Guangzhou